Pletal (Cilostazol) vs Top Alternatives: Best PAD Medication Guide

PAD Medication Comparison Tool
Use this tool to compare the key features of Pletal and its main alternatives for treating PAD. Adjust the sliders to simulate different patient profiles and see how these medications stack up.
Pletal (Cilostazol)
- Effectiveness: 30-40% improvement
- Cost: $150-$200/month
- Dosing: 100 mg twice daily
- Side Effects: Headache, diarrhea, palpitations
Pentoxifylline
- Effectiveness: 10-20% improvement
- Cost: $30-$60/month
- Dosing: 400 mg three times daily
- Side Effects: Nausea, dizziness, headache
Tadalafil
- Effectiveness: 35% improvement
- Cost: $70-$120/month
- Dosing: 5 mg daily
- Side Effects: Back pain, flushing, visual changes
Nicorandil
- Effectiveness: 25-30% improvement
- Cost: $80-$130/month
- Dosing: 5-10 mg twice daily
- Side Effects: Headache, flushing, rare ulceration
Recommended Option Based on Your Profile
Adjust the sliders to see personalized recommendations based on your walking goal and budget.
If you’ve been prescribed Pletal (Cilostazol) for intermittent claudication and are wondering whether there’s a cheaper, safer, or more effective option, you’re not alone. Many patients with peripheral arterial disease (PAD) start questioning if the drug truly fits their lifestyle, budget, or health profile. This guide breaks down how Pletal works, weighs it against the most common alternatives, and helps you decide which route makes the most sense for your legs and your wallet.
Key Takeaways
- Pletal improves walking distance by about 30‑40% in clinical trials, but its benefits plateau after a few months.
- Pentoxifylline offers modest gains at a lower price, though side‑effects like nausea are more frequent.
- Tadalafil, originally for erectile dysfunction, shows promising results for PAD with once‑daily dosing.
- Nicorandil combines vasodilation and nitrate effects, useful for patients who need both PAD relief and blood pressure control.
- Non‑drug options-structured exercise, aspirin, and revascularization-often complement or replace medication.
Below you’ll find the science, the stats, and the practical bits you need to talk confidently with your doctor.
Understanding Pletal and Its Role in PAD
Peripheral arterial disease (PAD) is a narrowing of the arteries that supply the legs, leading to pain called intermittent claudication. The condition affects roughly 8 million adults in the United States alone. Cilostazol, sold under the brand name Pletal, is a phosphodiesterase‑3 (PDE‑3) inhibitor. By raising cyclic AMP levels in vascular smooth muscle, it relaxes arteries and improves blood flow. It also has mild antiplatelet effects, which helps keep clots at bay.
Typical dosing is 100mg taken twice daily, with meals to reduce stomach upset. In the landmark CLEVER trial, patients on Pletal walked an average of 180 meters farther than those on placebo after 24 weeks. However, the drug isn’t suitable for everyone: people with heart failure, uncontrolled hypertension, or a history of bleeding should avoid it.

Top Alternatives to Pletal
When you hear the term Pletal alternatives, three names usually surface: Pentoxifylline, Tadalafil, and Nicorandil. Each works differently, costs differently, and carries its own set of pros and cons.
Pentoxifylline
Pentoxifylline is a methyl‑xanthine that improves red‑blood‑cell flexibility and reduces blood viscosity. The usual dose is 400mg three times daily. Studies show a 10‑20% improvement in walking distance-less than Pletal but still meaningful for many patients. Side effects include nausea, headache, and dizziness, which some find more bothersome than Pletal’s headache risk.
Tadalafil
Tadalafil is best known for treating erectile dysfunction, but its phosphodiesterase‑5 (PDE‑5) inhibition also dilates peripheral vessels. A daily 5mg dose has been investigated in PAD trials, showing up to a 35% increase in pain‑free walking time. The advantage? Once‑daily dosing and a lower incidence of gastrointestinal upset. However, it can cause back pain, vision changes, and isn’t advised for people on nitrates.
Nicorandil
Nicorandil combines a nitrate with a potassium‑channel opener, delivering dual vasodilatory action. The common regimen is 5‑10mg twice daily. Clinical data suggest a 25‑30% boost in walking distance, plus modest blood‑pressure lowering-useful if you’re juggling hypertension. Watch out for headaches, flushing, and, rarely, ulceration of the mouth or GI tract.
Non‑Pharmacologic Options
Medication isn’t the only path. Structured exercise programs (supervised treadmill walking 3‑5 times a week) can match or exceed drug benefits, especially when combined with antiplatelet therapy like aspirin or clopidogrel. For severe blockages, revascularization (angioplasty or bypass surgery) may be the definitive answer.
Side‑by‑Side Comparison
Medication | Mechanism | Typical Dose | Walking‑Distance Gain | Common Side Effects | Average Monthly Cost (US) |
---|---|---|---|---|---|
Pletal (Cilostazol) | PDE‑3 inhibition → vasodilation & antiplatelet | 100mg BID | ~30‑40% improvement | Headache, diarrhea, palpitations | $150‑$200 |
Pentoxifylline | Improves RBC flexibility, reduces viscosity | 400mg TID | ~10‑20% improvement | Nausea, dizziness, headache | $30‑$60 |
Tadalafil | PDE‑5 inhibition → peripheral vasodilation | 5mg daily | ~35% improvement | Back pain, flushing, visual changes | $70‑$120 |
Nicorandil | Nitrate + K‑ATP channel opener | 5‑10mg BID | ~25‑30% improvement | Headache, flushing, ulceration (rare) | $80‑$130 |

How to Pick the Right Option for You
Choosing isn’t just about numbers. Consider these real‑world factors:
- Medical History: Heart failure rules out Pletal; nitrate use eliminates Tadalafil.
- Budget: If out‑of‑pocket cost is a blocker, Pentoxifylline is the most affordable.
- Side‑Effect Tolerance: If headaches drive you crazy, Nicorandil’s flushing might be a better trade‑off.
- Convenience: Once‑daily dosing (Tadalafil) beats twice‑daily pills for busy lifestyles.
- Adjunct Therapies: Pairing any drug with a supervised walking program amplifies results by 20‑30%.
Bring this checklist to your next appointment. Your doctor can run a quick assessment-checking blood pressure, heart function, and any contraindications-then tailor a plan that may include one of these meds, a combination, or a non‑drug approach.
Frequently Asked Questions
Can I switch from Pletal to another drug without a washout period?
Generally you can transition directly, but your physician should monitor for overlapping side effects, especially if moving to another vasodilator. A short 2‑day overlap is sometimes advised to avoid a sudden drop in blood flow.
Is Pentoxifylline covered by most insurance plans?
Because Pentoxifylline is an older generic, many insurers list it as a Tier‑2 drug, meaning low co‑pay. Always check your specific plan’s formulary.
What if I have mild heart failure-can I still take Tadalafil for PAD?
Tadalafil is contraindicated with significant heart failure (NYHA Class III/IV). If your condition is mild (Class I/II) and you’re not on nitrates, a low dose may be permissible, but only under cardiology supervision.
Do I need to take aspirin alongside any of these medications?
Aspirin (81mg daily) is standard secondary prevention for PAD and works well with all four drugs. It reduces clot risk without major interactions, but discuss bowel‑bleed history with your doctor.
How soon can I expect to see improvement after starting a new PAD drug?
Most patients notice a modest boost in walking distance within 4‑6 weeks, with peak benefits around 3‑4 months. Consistency and pairing with exercise accelerate results.
Bottom line: there’s no one‑size‑fits‑all answer. Pletal alternatives each bring a mix of efficacy, safety, and cost that can line up with your personal health picture. Use the data above, chat openly with your clinician, and you’ll land on a plan that keeps you moving farther and feeling better.
- Oct, 10 2025
- Guy Boertje
- 1
- Permalink
- Tags:
- Pletal
- Cilostazol
- PAD medication alternatives
- compare Pletal
- peripheral arterial disease drugs
Written by Guy Boertje
View all posts by: Guy Boertje